top of page

Oxford Biodynamics PLC HY results webinar

Tue 30 May

|

Webinar

Jon Burrows, CEO presents the HY results which are released on 30th May and updates on current performance

Registration is closed
See other events
Oxford Biodynamics PLC HY results webinar
Oxford Biodynamics PLC HY results webinar

Time & Location

30 May 2023, 14:00 – 15:00

Webinar

About the event

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. OBD’s next product will be the Prostate Screening EpiSwitch® (PSE) blood test, due to be launched in Q4 2023. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Oxford BioDynamics has participated in more than 40 partnerships with big…

Share this event

bottom of page